Dermacyte® Amniotic Wound Care Liquid for the Treatment of Non-Healing Venous Stasis Ulcers
NCT ID: NCT04647240
Last Updated: 2025-02-25
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
PHASE2
50 participants
INTERVENTIONAL
2022-02-26
2025-10-15
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Two-Part, Randomized Study of Dermacyte® Amniotic Wound Care Matrix
NCT06444906
Dermacyte® Liquid for Treatment of Cutaneous Ulcers and Wounds
NCT06730022
Human Amniotic Membrane Grafting and Standard of Care Versus Standard of Care Alone in the Treatment of Venous Leg Ulcers
NCT01552447
Nonhealing Venous Leg Ulcers Treated With a Standard of Care (SoC) Alone or Standard of Care and Dehydrated Human Placenta Tissue (dHPT) With Crossover
NCT07230340
Real-World Effectiveness of Amniotic Membrane Allografts Versus Standard Wound Care in DFU, VLU, and PU
NCT07223281
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
In Part 2, approximately 30 subjects will be randomized 1:1 to receive Dermacyte Liquid or placebo (0.9% NaCl) with standard of care. Subjects will be followed for 12 weeks.
Subjects will receive localized subcutaneous injection of Dermacyte® Liquid or placebo into and/or around the wound bed during during clinic visits over a 12-week period and assessed for safety and efficacy measures at Screening, Baseline, and Weeks 4, 8, and 12. Percent reduction of the wound surface area will be formally collected at Baseline, Weeks 4, 8, and 12. To assess healing, the ulcer will be evaluated by assessing the change in the surface area (L X W) from Baseline. Overall change in VAS from Baseline to Week 12 will be evaluated and total wound closure will be evaluated at Week 12.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Dermacyte® Liquid (human amniotic fluid)
Dermacyte® Liquid (human amniotic fluid) solution 1.0mL to 2.0mL weekly
Dermacyte® Liquid (human amniotic fluid)
Subcutaneous injection into and/or around wound bed weekly
Placebo (0.9% saline)
Matching placebo solution 1.0mL to 2.0mL weekly
Dermacyte® Liquid (human amniotic fluid)
Subcutaneous injection into and/or around wound bed weekly
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Dermacyte® Liquid (human amniotic fluid)
Subcutaneous injection into and/or around wound bed weekly
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Males and female subjects aged 18 to 75 years inclusive at Screening (date the subject provides written informed consent to participate in study) for Part 1 only
* Males and female subjects aged 18 to 80 years inclusive at Screening (date the subject provides written informed consent to participate in study) for Part 2 only
* Subjects must have a full thickness ulcer that meets the following criteria:
* Ulcer surface area \> 1 cm2 and \< 25 cm2
* Ulcer surface area hasn't increased or decreased by 25% or more, as assessed within 14 days or more prior to Baseline
* Ulcer depth \> 0.2 cm at the deepest point of the wound, as measured by gently inserting a pre-moistened cotton tipped applicator into the deepest part of the wound.
* Ulcer age \< 12 months (365 days) prior to Baseline (for Part 2 only)
* Received \> 28 days of standard, conventional wound therapy with a high-compression, multilayer bandaging (e.g. compression hose, custom garments, commercial kits, etc.) prior to the Baseline visit. If clinically necessary, subjects may have received other wound treatments as needed (e.g., surgical debridement, pressure off-loading, negative pressure and/or hyperbaric oxygen therapy).
* Subjects must have previously undergone venous hemodynamic correction via compression, surgical venous stripping, sclerotherapy, endovenous laser ablation, and/or endovenous radiofrequency ablation.
* Subjects must have adequate circulation to the affected extremity as demonstrated by the most recently measured ankle-brachial index (ABI) greater than or equal to 0.8 and less than or equal to 1.2 or triphasic or biphasic Doppler arterial waveforms at the ankle of the affected leg (as applicable). If subject has undergone lower extremity stenting or bypass where ABI would be considered unreliable to assess microvascular circulation, subjects must have transcutaneous oximetry (TcPO2) \> 40 mmHg.
* Subjects must have VSU caused by underlying venous reflux disease with physiological reflux lasting greater than 500 milliseconds for superficial veins and 1.0 seconds for deep veins, as confirmed by most recent Doppler ultrasound venous mapping from Baseline; historical results/confirmation within the previous three years allowed.
* Subjects who agree to follow the specified precautions to avoid pregnancy as follows:
Subjects who are females of childbearing potential include any female subject who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation, or bilateral oophorectomy) or is not postmenopausal (defined as amenorrhea for at least 12 consecutive months). For female subjects of childbearing potential, a negative urine pregnancy test is required at Screening and Baseline prior to initiating Study Product. Female subjects of childbearing potential must follow 1 of the following approaches:
* Practice actual abstinence from intercourse
* Have a partner with a vasectomy
* Have an intrauterine device
* Must use 2 different forms of highly effective contraception for the duration of the study, and for at least 48 hours after discontinuing study drug. Medically acceptable forms of effective contraception include approved hormonal contraceptives (such as birth control pills) or barrier methods (such as a condom or diaphragm).
* Male subjects with a partner of childbearing potential must use a condom during intercourse for the duration of the study, and for 48 hours after discontinuing study drug.
* Subjects who, in the opinion of the Investigator, are capable of communicating effectively with study personnel and are considered reliable, willing, and likely to be cooperative with protocol requirements and attend all required study visits.
* Subjects who have the capability to answer surveys and questionnaires written in English.
Exclusion Criteria
* Ulcer must not have exposed bone, tendon, or ligament.
* Subject must not have another ulcer within 3 cm from the ulcer receiving investigational treatment.
* Female subjects who are pregnant, lactating, or planning to become pregnant during the study.
* Subjects actively receiving or received a skin graft substitutes within 30 days prior to Baseline.
* Subjects receiving oral, systemically administered, or lower extremity injectable corticosteroid therapy within 60 days prior to Baseline.
Subjects with angiographic or clinical signs of peripheral arterial disease (PAD) or congestive heart failure (CHF) with most previous echocardiogram demonstrating an ejection fraction (EF) less than 35%.
* Subjects with underlying osteomyelitis.
* Subjects with an active infection or condition that would interfere with interpretation of study assessments.
* Subjects with an HbA1c \> 7.0% (Part 1 only) or HbA1c \> 8.0% (Part 2 only), as collected at Screening or in the previous 120 days prior to Screening.
* Subjects with current deep vein thrombosis (DVT) (Part 2 only)
* Subjects with chronic musculoskeletal disorder or any other disease that would limit ambulation.
* Subjects with a history of alcohol abuse or illicit drug abuse within 12 months of Baseline which, in the Investigator's opinion, would make the subject inappropriate for enrollment in a clinical study.
* Subjects with any other concomitant disease with life expectancy of \<12 months from Baseline
* Subjects with an unstable psychiatric condition or those not capable of understanding the objectives, nature, or consequences of the study, or who have any condition which, in the Investigator's opinion, would constitute an unacceptable risk to the subject's safety.
* Subjects who are currently receiving an investigational drug, have an investigational device in place, or who have participated in an investigational drug or device study within 90 days prior to Baseline. Participation in an observational study within 90 days prior to Baseline does not disqualify a subject from enrolling.
* Subjects who have received another regenerative therapy within 30 days prior to Baseline.
* Subjects with a Body Mass Index (BMI) \> 45 (Part 2 only).
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
US Department of Veterans Affairs
FED
Merakris Therapeutics
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Compass Medical Research Center
Tucson, Arizona, United States
Center for Clinical Research, Inc.
Castro Valley, California, United States
Limb Preservation Platform, Inc.
Fresno, California, United States
Center for Clinical Research Inc.
San Francisco, California, United States
Center for Clinical Research, Inc.
San Francisco, California, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Northwell Health, Inc.
New Hyde Park, New York, United States
Brock Liden DPM
Circleville, Ohio, United States
Salem Vamc
Salem, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
YVETTE SPANGLER
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
DL-VSU-201
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.